Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-23-014779
Filing Date
2023-04-26
Accepted
2023-04-26 16:02:57
Documents
5
Period of Report
2023-04-26

Document Format Files

Seq Description Document Type Size
1 DEF 14A glue-def14a-2023.htm DEF 14A 954128
2 GRAPHIC img252893755_0.jpg GRAPHIC 9144
3 GRAPHIC img252893755_1.jpg GRAPHIC 9144
4 GRAPHIC img252893755_2.jpg GRAPHIC 137609
5 GRAPHIC img252893755_3.jpg GRAPHIC 296960
  Complete submission text file 0000950170-23-014779.txt   1574037
Mailing Address 645 SUMMER STREET SUITE 102 BOSTON MA 02210
Business Address 645 SUMMER STREET SUITE 102 BOSTON MA 02210 617-949-2643
Monte Rosa Therapeutics, Inc. (Filer) CIK: 0001826457 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40522 | Film No.: 23849643
SIC: 2836 Biological Products, (No Diagnostic Substances)